T1	Participants 121 189	patients <65 years with poor prognosis histologically aggressive NHL
T2	Participants 212 224	457 patients
T3	Participants 316 397	patients with poor prognosis histologically aggressive non-Hodgkin lymphoma (NHL)
T4	Participants 398 504	showing a response to initial CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy
T5	Participants 893 954	86% of patients in the CHOP arm had responded with 58% in CR.
T6	Participants 1284 1334	patients who attained CR and subsequently relapsed
